Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities

N. Tatsumi, N. Hojo, O. Yamada, M. Ogawa, Y. Katsura, S. Kawata, E. Morii, H. Sakamoto, R. Inaba, A. Tsuda, I. Fukuda, N. Moriguchi, Hidetoshi Hasuwa, M. Okabe, F. Fujiki, S. Nishida, H. Nakajima, A. Tsuboi, Y. Oka, N. HosenH. Sugiyama, Y. Oji

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.

Original languageEnglish
Pages (from-to)1003-1014
Number of pages12
JournalOncogene
Volume35
Issue number8
DOIs
Publication statusPublished - 2016 Feb 25
Externally publishedYes

Fingerprint

Urogenital Abnormalities
MicroRNAs
Myeloproliferative Disorders
Neoplasms
Hematopoietic Stem Cells
Wilms' Tumor Genes
Hematopoiesis
3' Untranslated Regions
Myeloid Cells
Knockout Mice
Small Interfering RNA
Carcinogenesis
Leukemia
Spleen

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Tatsumi, N., Hojo, N., Yamada, O., Ogawa, M., Katsura, Y., Kawata, S., ... Oji, Y. (2016). Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. Oncogene, 35(8), 1003-1014. https://doi.org/10.1038/onc.2015.154

Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. / Tatsumi, N.; Hojo, N.; Yamada, O.; Ogawa, M.; Katsura, Y.; Kawata, S.; Morii, E.; Sakamoto, H.; Inaba, R.; Tsuda, A.; Fukuda, I.; Moriguchi, N.; Hasuwa, Hidetoshi; Okabe, M.; Fujiki, F.; Nishida, S.; Nakajima, H.; Tsuboi, A.; Oka, Y.; Hosen, N.; Sugiyama, H.; Oji, Y.

In: Oncogene, Vol. 35, No. 8, 25.02.2016, p. 1003-1014.

Research output: Contribution to journalArticle

Tatsumi, N, Hojo, N, Yamada, O, Ogawa, M, Katsura, Y, Kawata, S, Morii, E, Sakamoto, H, Inaba, R, Tsuda, A, Fukuda, I, Moriguchi, N, Hasuwa, H, Okabe, M, Fujiki, F, Nishida, S, Nakajima, H, Tsuboi, A, Oka, Y, Hosen, N, Sugiyama, H & Oji, Y 2016, 'Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities', Oncogene, vol. 35, no. 8, pp. 1003-1014. https://doi.org/10.1038/onc.2015.154
Tatsumi N, Hojo N, Yamada O, Ogawa M, Katsura Y, Kawata S et al. Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. Oncogene. 2016 Feb 25;35(8):1003-1014. https://doi.org/10.1038/onc.2015.154
Tatsumi, N. ; Hojo, N. ; Yamada, O. ; Ogawa, M. ; Katsura, Y. ; Kawata, S. ; Morii, E. ; Sakamoto, H. ; Inaba, R. ; Tsuda, A. ; Fukuda, I. ; Moriguchi, N. ; Hasuwa, Hidetoshi ; Okabe, M. ; Fujiki, F. ; Nishida, S. ; Nakajima, H. ; Tsuboi, A. ; Oka, Y. ; Hosen, N. ; Sugiyama, H. ; Oji, Y. / Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities. In: Oncogene. 2016 ; Vol. 35, No. 8. pp. 1003-1014.
@article{543cb02bd28b4559bdae81335fe66bb7,
title = "Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities",
abstract = "The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.",
author = "N. Tatsumi and N. Hojo and O. Yamada and M. Ogawa and Y. Katsura and S. Kawata and E. Morii and H. Sakamoto and R. Inaba and A. Tsuda and I. Fukuda and N. Moriguchi and Hidetoshi Hasuwa and M. Okabe and F. Fujiki and S. Nishida and H. Nakajima and A. Tsuboi and Y. Oka and N. Hosen and H. Sugiyama and Y. Oji",
year = "2016",
month = "2",
day = "25",
doi = "10.1038/onc.2015.154",
language = "English",
volume = "35",
pages = "1003--1014",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities

AU - Tatsumi, N.

AU - Hojo, N.

AU - Yamada, O.

AU - Ogawa, M.

AU - Katsura, Y.

AU - Kawata, S.

AU - Morii, E.

AU - Sakamoto, H.

AU - Inaba, R.

AU - Tsuda, A.

AU - Fukuda, I.

AU - Moriguchi, N.

AU - Hasuwa, Hidetoshi

AU - Okabe, M.

AU - Fujiki, F.

AU - Nishida, S.

AU - Nakajima, H.

AU - Tsuboi, A.

AU - Oka, Y.

AU - Hosen, N.

AU - Sugiyama, H.

AU - Oji, Y.

PY - 2016/2/25

Y1 - 2016/2/25

N2 - The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.

AB - The Wilms' tumor gene WT1 is overexpressed in leukemia and solid tumors and has an oncogenic role in leukemogenesis and tumorigenesis. However, precise regulatory mechanisms of WT1 overexpression remain undetermined. In the present study, microRNA-125a (miR-125a) was identified as a miRNA that suppressed WT1 expression via binding to the WT1-3'UTR. MiR-125a knockout mice overexpressed WT1, developed myeloproliferative disorder (MPD) characterized by expansion of myeloid cells in bone marrow (BM), spleen and peripheral blood, and displayed urogenital abnormalities. Silencing of WT1 expression in hematopoietic stem/progenitor cells of miR-125a knockout MPD mice by short-hairpin RNA inhibited myeloid colony formation in vitro. Furthermore, the incidence and severity of MPD were lower in miR-125a (-/-) mice than in miR-125a (+/-) mice, indicating the operation of compensatory mechanisms for the complete loss of miR-125a. To elucidate the compensatory mechanisms, miRNA array was performed. MiR-486 was occasionally induced in compete loss of miR-125a and inhibited WT1 expression instead of miR-125a, resulting in the cancellation of MPD occurrence. These results showed for the first time the post-transcriptional regulatory mechanisms of WT1 by both miR-125a and miR-486 and should contribute to the elucidation of mechanisms of normal hematopoiesis and kidney development.

UR - http://www.scopus.com/inward/record.url?scp=84959514829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959514829&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.154

DO - 10.1038/onc.2015.154

M3 - Article

C2 - 25961914

AN - SCOPUS:84959514829

VL - 35

SP - 1003

EP - 1014

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 8

ER -